Drugs / Modified Measles Virus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02962167 | Feb 2017 → May 2023 | atypical teratoid rhabdoid tumor, childhood medulloblastoma | Sabine Mueller, MD, PhD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modified Measles Virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02962167 ↗ |
| Modality | Other / unclassified | “modified measles virus (MV-NIS)” NCT02962167 ↗ |
| Route | Other | “MV-NIS will be directly administered into the tumor bed following a standard of care surgical resection.” NCT02962167 ↗ |